Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has entered into a definitive agreement with an institutional healthcare investor for a $2 million private placement.

Under the terms of the agreement, Rosetta will issue unregistered convertible debentures (convertible into approximately 2.2 million ordinary shares) and warrants to purchase up to the same number of ordinary shares for gross proceeds of $2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.